Trial Profile

Effectiveness of the dual serotonin norepinephrine reuptake inhibitor venlafaxine in depressed patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atomoxetine (Primary) ; Paroxetine (Primary) ; Venlafaxine (Primary)
Indications Major depressive disorder
Focus Pharmacodynamics
Sponsors Wyeth

Most Recent Events

05 Jan 2022 rouet and form for"Atomoxetine" has been added from https://www.webmd.com/drugs/2/drug-64629/strattera-oral/details
27 Dec 2021 Results published in the International Journal of Neuropsychopharmacology
10 Jun 2010 Results preseneted at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com